Last reviewed · How we verify
bisoprolol 2.5mg
At a glance
| Generic name | bisoprolol 2.5mg |
|---|---|
| Also known as | concor |
| Sponsor | Zagazig University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- pErsonalised Nocebo Assessment of Beta-blockEr Symptoms in Heart Failure (NA)
- Efficacy and Safety of a Quadruple Ultra-low-dose Treatment for Hypertension (PHASE2)
- Rate Control Therapy Evaluation in Permanent Atrial Fibrillation (RATE-AF) (PHASE4)
- Preoperative Gabapentin Versus Bisoprolol for Hemodynamic Optimization During Sinus Surgery (PHASE4)
- Chronic Beta-blockade and Cardiopulmonary Exercise in COPD (PHASE4)
- Beta Blocker Therapy in Moderate to Severe COPD (PHASE4)
- Effect of Medical Treatment and Prognosis of Postural Orthostatic Tachycardia Syndrome (POTS) (PHASE4)
- Multidisciplinary Approach to Novel Therapies in Cardiology Oncology Research (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |